Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 152,173,904
  • Shares Outstanding, K 2,624,593
  • Annual Sales, $ 26,617 M
  • Annual Income, $ 3,196 M
  • 60-Month Beta 0.55
  • Price/Sales 5.71
  • Price/Cash Flow 18.05
  • Price/Book 10.59
Trade AZN with:

Options Overview

Details
  • Implied Volatility 19.32%
  • Historical Volatility 14.18%
  • IV Percentile 0%
  • IV Rank 1.38%
  • IV High 67.14% on 07/17/20
  • IV Low 18.65% on 06/15/21
  • Put/Call Vol Ratio 0.38
  • Today's Volume 2,718
  • Volume Avg (30-Day) 7,550
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 251,674
  • Open Int (30-Day) 250,344

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.54
  • Number of Estimates 3
  • High Estimate 0.66
  • Low Estimate 0.47
  • Prior Year 0.48
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
55.73 +5.95%
on 06/03/21
59.34 -0.50%
on 06/16/21
+1.57 (+2.74%)
since 05/24/21
3-Month
48.26 +22.35%
on 04/07/21
59.34 -0.50%
on 06/16/21
+10.25 (+21.02%)
since 03/24/21
52-Week
46.48 +27.03%
on 03/04/21
64.94 -9.08%
on 07/20/20
+6.91 (+13.26%)
since 06/24/20

Most Recent Stories

More News
Pharma Stock Roundup: EU Nod to AZN, SNY, JNJ Drugs, Glaxo's New COVID-19 Drug Data

EU approves AstraZeneca's (AZN) rare disease drug, Koselugo and expanded use of J&J's (JNJ) Darzalex Faspro and Sanofi's (SNY) Aubagio.

SNY : 52.41 (+0.63%)
AZN : 58.64 (+1.14%)
GSK : 39.71 (-0.35%)
JNJ : 163.21 (+0.36%)
PFE : 39.17 (+0.31%)
MRK : 76.20 (+0.82%)
LLY : 233.57 (+7.59%)
AstraZeneca (AZN) Rare Disorder Drug Koselugo Gets EU Nod

AstraZeneca's (AZN) Koselugo becomes the first medicine approved in Europe for neurofibromatosis type 1 plexiform neurofibromas.

AZN : 58.64 (+1.14%)
MRK : 76.20 (+0.82%)
BAYRY : 15.4200 (+1.51%)
BNTX : 230.33 (+0.36%)
AstraZeneca (AZN) Gets Court Order to Supply COVID-19 Jabs in EU

A court in Brussels orders AstraZeneca (AZN) to supply 80 million doses of its COVID-19 vaccine to Europe by Sep 27, 2021. The European Commission had requested for 300 million doses by end of September....

AZN : 58.64 (+1.14%)
JNJ : 163.21 (+0.36%)
PFE : 39.17 (+0.31%)
EBS : 61.39 (+2.23%)
Pharma Stock Roundup: AZN COVID-19 Antibody Cocktail Failure, GSK New Cancer Deal

AstraZeneca's (AZN) phase III study on COVID-19 antibody cocktail fails to meet primary goal. Glaxo (GSK) signs a new co-development/commercialization deal for a cancer candidate with iTeos Therapeutics....

AZN : 58.64 (+1.14%)
GSK : 39.71 (-0.35%)
PFE : 39.17 (+0.31%)
MRK : 76.20 (+0.82%)
LLY : 233.57 (+7.59%)
Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know

Astrazeneca (AZN) closed at $58.35 in the latest trading session, marking a -0.1% move from the prior day.

AZN : 58.64 (+1.14%)
AstraZeneca (AZN) Antibody Cocktail Fails to Prevent COVID-19

AstraZeneca's (AZN) antibody cocktail, AZD7442 fails to prevent people who were already infected from developing symptomatic COVID-19. However, it showed some efficacy in people who were not infected.

REGN : 539.23 (+1.78%)
AZN : 58.64 (+1.14%)
GSK : 39.71 (-0.35%)
LLY : 233.57 (+7.59%)
The Zacks Analyst Blog Highlights: Salesforce, Shopify, AstraZeneca, Micron and Ecolab

The Zacks Analyst Blog Highlights: Salesforce, Shopify, AstraZeneca, Micron and Ecolab

AZN : 58.64 (+1.14%)
CRM : 246.11 (+1.77%)
ECL : 208.43 (+0.17%)
MU : 80.54 (+1.92%)
SHOP : 1,519.31 (+1.25%)
Top Research Reports for salesforce, Shopify & AstraZeneca

Top Research Reports for salesforce, Shopify & AstraZeneca

SHOP : 1,519.31 (+1.25%)
PLD : 121.06 (-0.05%)
MU : 80.54 (+1.92%)
ECL : 208.43 (+0.17%)
CRM : 246.11 (+1.77%)
AZN : 58.64 (+1.14%)
Worldwide Nanomedicines Industry to 2026 - Featuring 3M, Thermo Fisher Scientific and Eli Lily & Co Among Others

/PRNewswire/ -- The report has been added to offering.

AZN : 58.64 (+1.14%)
CELGZ : 0.47 (+2.15%)
MRK : 76.20 (+0.82%)
PFE : 39.17 (+0.31%)
SNN : 43.45 (+0.72%)
Nearly $ 30 Billion growth expected in Global Type 2 Diabetes Market during 2021-2025 | Technavio

/PRNewswire/ - The type 2 diabetes market is expected to grow by during 2021-2025, according to Technavio. The report offers a detailed analysis of the impact of the COVID-19 pandemic on the type 2 diabetes...

AZN : 58.64 (+1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Key Turning Points

3rd Resistance Point 59.56
2nd Resistance Point 59.21
1st Resistance Point 58.59
Last Price 58.64
1st Support Level 57.62
2nd Support Level 57.27
3rd Support Level 56.65

See More

52-Week High 64.94
Last Price 58.64
Fibonacci 61.8% 57.89
Fibonacci 50% 55.71
Fibonacci 38.2% 53.53
52-Week Low 46.48

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar